# Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease

> **NCT00353756** · PHASE1 · UNKNOWN · sponsor: **Avidia** · enrollment: 52 (—)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** C326, IL-6 Inhibitory Avimer protein

## Key facts

- **NCT ID:** NCT00353756
- **Lead sponsor:** Avidia
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 52 (—)
- **Last updated:** 2006-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00353756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00353756, "Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00353756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*